Innovation

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint1. Topline results showed a significant proportion of patients treated with iptacopan (200 mg twice daily…

Reimagine MedicineMedical InnovationsInnovation
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III APPLY-PNH trial1. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinuria (PNH) who received the investigational oral monotherapy iptacopan achieved clinically meaningful increases in hemoglobin levels compared to anti-C5…

Reimagine MedicineMedical InnovationsInnovation
Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation

Annonce événementielle au sens de l’art. 53 RCExercice entier

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis continues to grow with further core margin expansion and achieves important innovation milestones

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials conducted in HS, Cosentyx treatment response rates continued to improve beyond…

Reimagine MedicineInnovation
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe

Annonce événementielle au sens de l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe

Annonce événementielle au sens de l’art. 53 RC

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022

Ad-hoc-Mitteilung gemäss Art. 53 KR

Reimagine MedicineMedical InnovationsInnovationAd Hoc
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years

Basel, November 7, 2022 — Novartis today announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-…

Reimagine MedicineMedical InnovationsInnovation
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Ad hoc announcement pursuant to Art. 53 LR

Reimagine MedicineMedical InnovationsInnovationAd Hoc